“…Single BRAF V600E detection with promising cost‐effectiveness studies 8 , 9 was expanded to cancer hotspot panels, to larger gene panels recently. 10 , 11 , 12 , 13 , 14 In Bethesda III or V cytology cases in particular, MD may help direct a change in management. In contrast, MD would, with rare exceptions, not cause an alteration in management in case of Bethesda IV, in the setting of current (Dutch) guidelines.…”